Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.
The potential impact of pandemic influenza makes effective measures to limit the spread and morbidity of virus infection a public health priority. Antiviral drugs are seen as essential requirements for control of initial influenza outbreaks caused by a new virus, and in pre-pandemic plans there is a heavy reliance on drug stockpiles. The principal target for these drugs is a virus surface glycoprotein, neuraminidase, which facilitates the release of nascent virus and thus the spread of infection. Oseltamivir (Tamiflu) and zanamivir (Relenza) are two currently used neuraminidase inhibitors that were developed using knowledge of the enzyme structure. It has been proposed that the closer such inhibitors resemble the natural substrate, the less likely they are to select drug-resistant mutant viruses that retain viability. However, there have been reports of drug-resistant mutant selection in vitro and from infected humans. We report here the enzymatic properties and crystal structures of neuraminidase mutants from H5N1-infected patients that explain the molecular basis of resistance. Our results show that these mutants are resistant to oseltamivir but still strongly inhibited by zanamivir owing to an altered hydrophobic pocket in the active site of the enzyme required for oseltamivir binding. Together with recent reports of the viability and pathogenesis of H5N1 (ref. 7) and H1N1 (ref. 8) viruses with neuraminidases carrying these mutations, our results indicate that it would be prudent for pandemic stockpiles of oseltamivir to be augmented by additional antiviral drugs, including zanamivir.
Collins
Patrick J
PJ
MRC-National Institute for Medical Research, Mill Hill, London NW7 1AA, UK.
Haire
Lesley F
LF
Lin
Yi Pu
YP
Liu
Junfeng
J
Russell
Rupert J
RJ
Walker
Philip A
PA
Skehel
John J
JJ
Martin
Stephen R
SR
Hay
Alan J
AJ
Gamblin
Steven J
SJ
D001665:Binding Sites; D018360:Crystallography, X-Ray; D024882:Drug Resistance, Viral; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D053124:Influenza A Virus, H5N1 Subtype / Q000187:drug effects* / Q000201:enzymology* / Q000235:genetics; D007251:Influenza, Human / Q000821:virology; D007700:Kinetics; D008958:Models, Molecular; D008968:Molecular Conformation; D009154:Mutation / Q000235:genetics*; D009439:Neuraminidase / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism; D053139:Oseltamivir / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding; D053243:Zanamivir / Q000494:pharmacology
D004791:Enzyme Inhibitors; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir